Breast Cancer Screening Is Not One-Size-Fits-All

Breast cancer myths are everywhere. The facts should not be so difficult to find.

In a recent discussion about her book The Breast Advice, Dr. Elisa Port, chief of breast surgery at Mount Sinai, addressed many of the questions women encounter when trying to understand breast cancer risk, screening, diagnosis, and treatment. Her broader message is an important one: women deserve clear information, and they should be able to participate meaningfully in decisions about their care.

One of the most persistent problems is the way screening recommendations are presented as though one schedule must be right for everyone. Guidelines are valuable, but they are written for populations. A thoughtful screening plan also considers the individual woman.

Mammography Is the Foundation, Not the Entire Conversation

The U.S. Preventive Services Task Force recommends screening mammography every two years for women ages 40 through 74 who are at average risk. Other medical organizations differ somewhat on whether screening should be annual or biennial and how long it should continue.

These differences do not mean that mammography is ineffective or that physicians cannot agree on anything. They reflect different interpretations of the balance among earlier detection, false-positive findings, additional biopsies, overdiagnosis, radiation exposure, and patient preference.

For an average-risk woman, a guideline-based schedule may be entirely appropriate. For someone at increased risk, it may not be enough.

Risk Assessment Should Come Before the Mammogram Reminder

Age is only one part of breast cancer risk. A more individualized discussion may include:

• Breast or ovarian cancer in close relatives
• The ages at which relatives were diagnosed
• Known inherited mutations such as BRCA1, BRCA2, PALB2, CHEK2, or others
• A previous breast cancer diagnosis
• Prior atypical hyperplasia, lobular carcinoma in situ, or certain biopsy findings
• Breast density
• Chest radiation at a young age
• Reproductive, hormonal, and lifestyle history
• Current age, health status, and estimated life expectancy

Family history also needs more nuance than asking whether a woman’s mother had breast cancer. The father’s side of the family matters. Ovarian, pancreatic, prostate, and male breast cancers may also provide clues to an inherited cancer syndrome.

Many women who develop breast cancer do not have a close relative with the disease. The absence of family history should therefore never be interpreted as proof that screening is unnecessary.

Dense Breasts Change the Discussion

Breast density describes the amount of fibroglandular tissue visible on a mammogram. It cannot be reliably determined by how the breasts look or feel.

Dense tissue matters for two reasons. It can make some cancers more difficult to see on mammography, and it is independently associated with a higher risk of developing breast cancer.

Since September 2024, the FDA has required mammography facilities to notify patients whether their breasts are dense or not dense. That notification is useful, but it does not automatically answer what should happen next.

Dense breasts alone do not mean that every woman needs an ultrasound or MRI. Supplemental imaging may find cancers that mammography misses, but it can also increase false-positive findings, follow-up imaging, cost, anxiety, and unnecessary biopsies. The decision should consider the woman’s complete risk profile, not density in isolation.

When MRI May Be Appropriate

The American Cancer Society recommends annual breast MRI together with mammography for many women at high risk, including certain women with an estimated lifetime breast cancer risk of approximately 20% to 25% or greater.

MRI is generally used in addition to mammography rather than as a replacement. The two tests can identify different findings. MRI is more sensitive, but that sensitivity also means it is more likely to detect abnormalities that ultimately are not cancer.

Ultrasound, contrast-enhanced mammography, and other technologies may be considered in selected situations. The most appropriate study depends on risk, breast density, prior imaging, access, contraindications, and the clinical question being asked.

Screening Is Not the Same as Diagnostic Evaluation

A screening mammogram is intended for someone without a new breast symptom. A new lump, nipple discharge, skin retraction, persistent focal pain, nipple change, or other concerning finding requires clinical evaluation. It should not simply wait for the next routine screening appointment.

Diagnostic imaging may involve specialized mammographic views, ultrasound, MRI, or biopsy depending on the finding. A recent normal mammogram does not mean that a new or persistent change should be ignored.

Common Myths That Create False Reassurance or Fear

Myth: “Breast cancer does not run in my family, so I am not at risk.”
Most breast cancers are not explained by a known inherited mutation or an obvious family history. Family history can increase risk, but its absence does not eliminate it.

Myth: “If I do not feel a lump, I do not need screening.”
The purpose of screening is to identify concerning changes before they can be felt or cause symptoms.

Myth: “A normal mammogram guarantees that there is no cancer.”
No screening test is perfect. Mammographic sensitivity can be reduced in dense tissue, and some cancers may become apparent between scheduled screenings.

Myth: “Thermography can replace mammography.”
Thermography has not been established as an effective replacement for mammography. Relying on it alone may delay appropriate detection and evaluation.

Myth: “More imaging is always better.”
Additional imaging can be valuable when it is matched to risk. Used indiscriminately, it can also create false alarms, unnecessary procedures, and expense without a clear improvement in outcomes.

Myth: “Every abnormal mammogram means cancer.”
Most callbacks do not result in a cancer diagnosis. Additional images are often needed to clarify overlapping tissue, technical limitations, cysts, calcifications, or other findings.

Hormone Therapy Requires the Same Individualized Thinking

Discussions about menopause hormone therapy are frequently reduced to the claim that hormones either cause breast cancer or are completely risk-free. Neither statement is responsible.

Risk depends on the formulation, route, dose, duration, age at initiation, personal breast history, family history, and other health factors. Women with a personal history of breast cancer or significant inherited risk require particularly careful specialist guidance.

At HormoneSynergy®, decisions about bioidentical hormone optimization are made within a broader assessment of cardiovascular, metabolic, breast, bone, cognitive, and overall health. Hormones are medical tools, not lifestyle accessories, and should be prescribed with appropriate screening and follow-up.

Questions Worth Asking

Women should feel comfortable asking their clinician:

• Am I considered average, intermediate, or high risk?
• Has my lifetime breast cancer risk been formally estimated?
• Are my breasts dense, and how does that affect my screening?
• Should I begin screening earlier or be screened annually?
• Would genetic counseling be appropriate based on both sides of my family?
• Would MRI or another form of supplemental imaging meaningfully help me?
• What are the potential benefits and drawbacks of additional screening?
• How should my screening plan change as I age or if my health changes?

Medicine, Not Myth

Good screening is neither casual reassurance nor reflexively ordering every available test. It is the process of matching the right evaluation to the right person at the right time.

Mammography saves lives, but a mammogram reminder is not the same as a complete breast cancer risk assessment. Women deserve to know what their breast density means, whether their family history suggests inherited risk, what additional screening can and cannot accomplish, and when a new symptom requires diagnostic care.

Breast cancer screening is not one-size-fits-all because women are not one-size-fits-all.

Frequently Asked Questions

At what age should women begin mammograms?

The USPSTF recommends biennial mammography from ages 40 through 74 for average-risk women. Other organizations support annual screening beginning at age 40 or allow somewhat different schedules. Women at increased risk may need to begin earlier.

Do dense breasts mean I need an MRI?

Not automatically. Dense tissue can reduce mammographic sensitivity and increase breast cancer risk, but decisions about MRI or ultrasound should also consider family history, genetics, previous biopsies, calculated risk, and the potential for false-positive findings.

Can ultrasound replace a mammogram?

Ultrasound is generally used as a diagnostic or supplemental test, not as a routine replacement for mammography. It may identify some findings that are difficult to see on a mammogram but can also produce additional false positives.

Should I get genetic testing if breast cancer runs in my family?

Genetic counseling may be appropriate when breast, ovarian, pancreatic, prostate, or male breast cancers appear in a family, particularly when diagnoses occurred at younger ages. Testing is most informative when guided by a qualified clinician or genetic counselor.

Does a normal mammogram mean I can ignore a new lump?

No. A new or persistent breast change should be evaluated even after a normal mammogram. Screening and diagnostic evaluation serve different purposes.